HUE047357T2 - Gyógyászati kezelés - Google Patents

Gyógyászati kezelés

Info

Publication number
HUE047357T2
HUE047357T2 HUE12715421A HUE12715421A HUE047357T2 HU E047357 T2 HUE047357 T2 HU E047357T2 HU E12715421 A HUE12715421 A HU E12715421A HU E12715421 A HUE12715421 A HU E12715421A HU E047357 T2 HUE047357 T2 HU E047357T2
Authority
HU
Hungary
Prior art keywords
therapeutic treatment
therapeutic
treatment
Prior art date
Application number
HUE12715421A
Other languages
English (en)
Inventor
Barry Davies
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUE047357T2 publication Critical patent/HUE047357T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE12715421A 2011-04-01 2012-04-02 Gyógyászati kezelés HUE047357T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161470668P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
HUE047357T2 true HUE047357T2 (hu) 2020-04-28

Family

ID=45976963

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12715421A HUE047357T2 (hu) 2011-04-01 2012-04-02 Gyógyászati kezelés

Country Status (26)

Country Link
US (2) US9402847B2 (hu)
EP (2) EP2694056B1 (hu)
JP (1) JP6080837B2 (hu)
KR (1) KR101851820B1 (hu)
CN (1) CN103442708B (hu)
AU (1) AU2012235902B2 (hu)
BR (1) BR112013025410A2 (hu)
CA (1) CA2831848C (hu)
CY (1) CY1122608T1 (hu)
DK (1) DK2694056T3 (hu)
EA (1) EA027506B1 (hu)
ES (1) ES2761311T3 (hu)
HR (1) HRP20191927T1 (hu)
HU (1) HUE047357T2 (hu)
IL (1) IL228589B (hu)
LT (1) LT2694056T (hu)
ME (1) ME03589B (hu)
MX (1) MX357447B (hu)
MY (1) MY169449A (hu)
PL (1) PL2694056T3 (hu)
PT (1) PT2694056T (hu)
RS (1) RS59568B1 (hu)
SG (1) SG193505A1 (hu)
SI (1) SI2694056T1 (hu)
WO (1) WO2012131399A1 (hu)
ZA (1) ZA201308176B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012235902B2 (en) * 2011-04-01 2015-08-27 Astrazeneca Ab Therapeutic treatment
KR102222346B1 (ko) 2013-03-04 2021-03-02 아스트라제네카 아베 조합 치료
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (hu) 1963-04-04 1900-01-01
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
CN100462066C (zh) 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
DE69830409T2 (de) 1997-08-05 2006-01-26 Pfizer Products Inc., Groton 4-aminopyrrole[3,2-d]pyrimidine als neuropeptid rezeptor antagonisten
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
BR9910864A (pt) 1998-06-04 2002-02-05 Abbott Lab Compostos anti-inflamatórios para inibição de aderência celular
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
PT1294724E (pt) 2000-06-26 2006-07-31 Pfizer Prod Inc Compostos pirrolo (2,3-d ) pirimidina como agentes imunosupressivos
BR0113585A (pt) 2000-08-31 2003-07-29 Hoffmann La Roche Derivados quinazolina como antagonistas adrenérgicos alfa-1
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
PL363245A1 (en) 2000-12-01 2004-11-15 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1
UY27220A1 (es) * 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
DK1474425T3 (da) 2002-01-07 2006-09-25 Eisai Co Ltd Deazapuriner og anvendelser deraf
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
WO2003097164A1 (en) * 2002-05-17 2003-11-27 Aventis Pharma S.A. Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2004002531A1 (ja) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 血管の収縮または拡張による疾患治療剤
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
AU2003290673B2 (en) 2002-11-08 2011-01-06 Massachusetts Institute Of Technology Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
NZ540495A (en) 2002-12-04 2007-09-28 Eisai R&D Man Co Ltd 1,3-Dihydro-imidazole fused-ring compound
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
EP1601357A4 (en) 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
AU2004232392A1 (en) 2003-04-21 2004-11-04 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (Purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
EP1698375B1 (en) 2003-12-25 2014-04-02 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
CN103054798B (zh) 2005-08-31 2021-03-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
NZ592132A (en) 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
WO2007125320A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP2029592A1 (en) 2006-04-25 2009-03-04 Astex Therapeutics Limited Pharmaceutical compounds
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
JP5406039B2 (ja) 2006-12-21 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
RS53552B1 (en) * 2007-10-11 2015-02-27 Astrazeneca Ab DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B
AU2012235902B2 (en) * 2011-04-01 2015-08-27 Astrazeneca Ab Therapeutic treatment

Also Published As

Publication number Publication date
CN103442708B (zh) 2016-11-09
CA2831848A1 (en) 2012-10-04
ES2761311T3 (es) 2020-05-19
RS59568B1 (sr) 2019-12-31
EP2694056A1 (en) 2014-02-12
MX357447B (es) 2018-07-10
AU2012235902A1 (en) 2013-05-02
PL2694056T3 (pl) 2020-03-31
DK2694056T3 (da) 2020-01-02
HRP20191927T1 (hr) 2020-01-10
KR101851820B1 (ko) 2018-06-04
LT2694056T (lt) 2019-12-10
CY1122608T1 (el) 2021-03-12
EP2694056B1 (en) 2019-10-16
JP2014509639A (ja) 2014-04-21
EA201391327A1 (ru) 2014-03-31
IL228589A0 (en) 2013-12-31
BR112013025410A2 (pt) 2016-12-20
JP6080837B2 (ja) 2017-02-15
EA027506B1 (ru) 2017-08-31
MY169449A (en) 2019-04-11
EP3620159A1 (en) 2020-03-11
IL228589B (en) 2019-09-26
AU2012235902B2 (en) 2015-08-27
ME03589B (me) 2020-07-20
US9402847B2 (en) 2016-08-02
SI2694056T1 (sl) 2019-12-31
US20140121227A1 (en) 2014-05-01
SG193505A1 (en) 2013-10-30
CN103442708A (zh) 2013-12-11
ZA201308176B (en) 2015-12-23
PT2694056T (pt) 2019-11-20
MX2013011413A (es) 2014-05-21
NZ616410A (en) 2015-09-25
US20160317540A1 (en) 2016-11-03
WO2012131399A1 (en) 2012-10-04
CA2831848C (en) 2020-12-22
KR20140022856A (ko) 2014-02-25

Similar Documents

Publication Publication Date Title
ZA201305897B (en) Combination therapy
EP2906208A4 (en) THERAPEUTIC TREATMENT
ZA201400120B (en) Combination therapy
EP2740420A4 (en) THERAPEUTIC TOOL
EP2737867A4 (en) THERAPEUTIC TREATMENT APPARATUS
ZA201502595B (en) Therapeutic methods
EP2701744A4 (en) COMBINATION THERAPY
ZA201308176B (en) Therapeutic treatment
ZA201308117B (en) Avian-based treatment
GB201115761D0 (en) Therapeutic treatments
GB201115759D0 (en) Therapeutic treatments
GB201111247D0 (en) Treatment
GB201109119D0 (en) Treatment
GB201102270D0 (en) Treatment
GB201102266D0 (en) Treatment
GB201102288D0 (en) Treatment
GB201102272D0 (en) Treatment
GB201102282D0 (en) Treatment
GB201102277D0 (en) Treatment
GB201102263D0 (en) Treatment
GB201102276D0 (en) Treatment
GB201102275D0 (en) Treatment
GB201102273D0 (en) Treatment
GB201102271D0 (en) Treatment
GB201102274D0 (en) Treatment